

UNWANTED EFFECTS OF COSMETICS AND DRUGS USED IN DERMATOLOGY

Second edition

Johan P. Nater

Anton C. de Groot

Dhiam H. Liem

1985

ELSEVIER – Amsterdam – New York – Oxford

UNWANTED EFFECTS OF COSMETICS AND DRUGS USED IN DERMATOLOGY

Second edition

Johan P. Nater

Department of Dermatology, Academic Hospital
State University of Groningen
Groningen, The Netherlands

Anton C. de Groot

Departments of Dermatology
Carolus Hospital and Willem-Alexander Hospital
's-Hertogenbosch, The Netherlands

Co-author for the section on cosmetology:

Dhiam H. Liem

Food Inspection Service
Cosmetics Department
Enschede, The Netherlands

1985

ELSEVIER – Amsterdam – New York – Oxford

© Elsevier Science Publishers B.V., 1985

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher, Elsevier Science Publishers B.V./Biomedical Division, P.O. Box 1126, 1000 BC Amsterdam, The Netherlands.

Special regulations for readers in the USA – This publication has been registered with the Copyright Clearance Center Inc. (CCC), Salem, Massachusetts. Information can be obtained from the CCC about conditions under which photocopies of parts of this publication may be made in the USA. All other copyright questions, including photocopying outside of the USA, should be referred to the publisher.

ISBN 0 444 90358 5

Notice The authors and publisher of this work have made every effort to ensure that the drug dosage schedules herein are accurate and in accord with the standards accepted at the time of publication. Readers are advised, however, to check the product information sheet included in the package of each drug prior to administration to be certain that changes have not been made in either the recommended dose or contra-indications. Such verification is especially important in regard to new or infrequently used drugs.

Published by:

Elsevier Science Publishers B.V.
P.O. Box 1126,
1000 BC Amsterdam

Sole distributors for the USA and Canada:

Elsevier Science Publishing Co. Inc.
52 Vanderbilt Avenue
New York, NY 10017

Printed in the Netherlands by Casparie-Amsterdam

Preface

While preparing the manuscript for the first edition of this book on side effects of cosmetics and (local and systemic) drugs used by the dermatologist, we intended it to become a reference work with the following characteristics: comprehensiveness, easy to use, easy location of relevant information, copiously referenced, and up to date.

We did not know whether and how this 'encyclopaedic approach', providing many alphabetically listed tables while keeping the text to a minimum, so fundamentally different from the major textbooks in this and adjacent areas, would be appreciated. Several reviews in some major dermatological and cosmological periodicals, as well as many letters from readers proved this 'formula' to be well accepted, and encouraged us in our view that the data provided in this way filled a need.

Stimulated and encouraged by this response and realizing that the fastly increasing amount of information in this field makes it difficult for any reference book to remain up to date, we hereby present a second, enlarged edition, two years after the first edition was released. This second edition has been revised according to new experiences, new publications and helpful advice from many users of the book. Apart from updating and completing the existing text, some important subjects have been added. Chapter 13, 'Drugs used on the oral mucosa', has been extended to the discussion of topical and systemic side effects of drugs used on the vulvo-vaginal mucosa and drugs used in ophthalmological practice. This chapter has accordingly been renamed 'Drugs used on the mucosae'.

Many more topical drugs and cosmetics which were found to have caused systemic side effects are discussed in Chapter 16. We found it appropriate (though it seems somewhat paradoxical) to include in this chapter a section on 'Transdermal drug delivery systems', where percutaneous absorption of topically applied drug, is exploited for therapeutic purposes. Examples are nitroglycerin, scopolamine and clonidine.

Chapter 19 has been updated with a comprehensive survey on adverse effects of oral retinoids. Although there can be no doubt that this group of vitamin-A analogs, notably etretinate and isotretinoin, is a very valuable addition to the therapeutic armamentarium of the dermatologist, he should be conscious of the fact that many side effects, some serious, may occur. Also new in this chapter are ketoconazole and acyclovir, drugs which, thus far, appear to have relatively low toxicity profiles.

Throughout the text, many more patch test concentrations and vehicles have been listed, thus facilitating adequate investigation in cases of suspected contact allergic reactions.

Approximately 800 new references have been added. This should enable easy access to further relevant information for any one wanting to know more about a particular drug or side effect.

Last but not least, an extensive alphabetic index of all compounds mentioned in the text has been compiled, including synonyms and trade names.

The authors wish to acknowledge their indebtedness to the many dermatologists, whose observations have been incorporated in this volume. We hope that the users of this book will continue to share their criticisms and suggestions for improvements with us.

J.P. Nater
A.C. de Groot

Table of contents

SECTION I. LOCAL SIDE EFFECTS OF TOPICAL DRUGS

Chapter 1.	Contact dermatitis	1
	Introduction	1
	Morphological aspects of contact dermatitis	1
Chapter 2.	Toxic and irritant contact dermatitis	2
	Acute toxic contact dermatitis	2
	Irritant contact dermatitis	2
	Irritant dermatitis due to topical drugs	3
Chapter 3.	Allergic contact dermatitis (general aspects)	6
	Immunological aspects	6
	The technique of patch testing	7
	Classification of patch test reactions	9
	Patch testing with topically applied medicaments	9
	The test concentration	10
	The vehicle to be used for patch testing	10
	Photopatch testing	10
	The interpretation of patch test results	11
	List of (pseudo) cross-reactions	17
	Risks of patch testing for the patient	26
	The use of patch tests in drug eruptions	27
	Predictive tests to identify allergens	29
	The persistence of acquired epidermal sensitivity	30
	Patch testing on the oral mucosa	31
Chapter 4.	Unusual manifestations of allergic contact sensitivity	36
	Purpuric allergic contact dermatitis	36
	Pigmented contact dermatitis	36
	Follicular contact dermatitis	37
	Erythema multiforme-like eruptions	37
	Contact urticaria	38
	Lichenoid eruptions	38
	Contact granuloma	38
	Focal contact sensitivity	39
	Toxic epidermal necrolysis (Lyell)	39
	Lymphomatoid contact dermatitis	39
	Allergic contact dermatitis complicated by extracutaneous symptoms	40
	Miscellaneous	41
Chapter 5.	Allergic contact dermatitis from topical drugs	44
	Preservatives: antimicrobials and antioxidants	45

	Fragrance materials	53
	Local anesthetics	60
	Vehicle constituents	62
	Antibiotics and chemotherapeutics	67
	Antihistamines	70
	Antimycotics	72
	Corticosteroids	75
	Drugs used in the treatment of psoriasis, acne, eczema and pruritus	77
	Plant-derived substances in topical drugs	79
	Antiparasitic drugs	82
	Miscellaneous drugs	82
	Pigments used in tattoos	86
	Accidental contactants	87
Chapter 6.	Phototoxic and photoallergic contact dermatitis	109
	Photosensitivity due to topical photosensitizers (photocontact dermatitis)	110
Chapter 7.	The contact urticaria syndrome	119
	Contact urticaria caused by topical drugs	120
Chapter 8.	Necrosis of the skin and the mucous membranes due to topical drugs	129
Chapter 9.	Acne-folliculitis	130
Chapter 10.	Discoloration of the skin and appendages	132
Chapter 11.	Stinging sensation due to ingredients of cosmetics and topical pharmaceutical preparations	137
Chapter 12.	Miscellaneous side effects	138
Chapter 13.	Drugs used on the mucosae	143
	Drugs used on the oral mucosa	143
	Toothpastes	143
	Other oral medication	145
	Mouth fresheners	147
	Drugs used on the vaginal mucosa	149
	Drugs used in ophthalmological practice	150
	Systemic effects	151
	Local side effects	155
Chapter 14.	Local side effects of corticosteroids	162
	Topical corticosteroid preparations	163
	Topical corticosteroid-antibiotic preparations	166

SECTION II. SYSTEMIC SIDE EFFECTS OF TOPICAL DRUGS

Chapter 15:	Percutaneous absorption of topically applied drugs	170
	Factors influencing absorption	170
Chapter 16:	Systemic side effects caused by topically applied drugs and cosmetics	172
	<i>Anaphylactic reactions to topically applied drugs and cosmetics</i>	172
	<i>Toxic action of topically applied drugs and cosmetics</i>	172
	Arsenic	172
	Benzocaine	173
	Boric acid	173
	Camphor	174
	Carmustine (BCNU)	175
	Castellani's solution	175
	Chloramphenicol	176
	Clindamycin	176
	Coal tar	177
	Corticosteroids	177
	Diethyltoluamide	178
	Dimethyl sulfoxide	179
	Dinitrochlorobenzene (DNCB)	179
	Diphenylpyraline hydrochloride	180
	Dithranol (cignolin, anthralin)	180
	Ethyl alcohol	180
	Fumaric acid monoethyl ester	181
	Gentamicin	181
	Henna dye and p-phenylenediamine	182
	Hexachlorophene	182
	4-Homosulfanilamide	184
	Iodine	184
	Lead	184
	Lidocaine	185
	Lindane	185
	Malathion	187
	Mercury and mercurial compounds	187
	Monobenzene	189
	2-Naphthol	190
	Neomycin	190
	Phenol (carbolic acid)	191
	Podophyllum resin	193
	Povidone-iodine	194
	Promethazine	195
	Quinine analogs	196
	Resorcinol	197
	Salicylic acid	197

	Selenium sulfide	199
	Sex hormones	199
	Silver nitrate	200
	Sulfadiazine silver	200
	Sulfur	201
	Tretinoin	202
	Triclocarban	202
	Triphenylmethane dyes	203
	Transdermal drug delivery systems	203
	Clonidine	203
	Glycopyrrolate	203
	Nitroglycerin	204
	Scopolamine	204
 SECTION III. DERMATITIS MEDICAMENTOSA AND PHOTOCHEMOTHERAPY		
Chapter 17.	Systemic eczematous contact-type dermatitis medicamentosa	215
Chapter 18.	Side effects of photochemotherapy	221
	PUVA therapy	221
	Oncogenic effects of the Goeckerman regimen	236
 SECTION IV. SIDE EFFECTS OF SYSTEMIC DRUGS USED IN DERMATOLOGY		
Chapter 19.	Side effects of systemic drugs used in dermatology	245
	Corticosteroids	245
	Cytostatic and immunosuppressive drugs	248
	Antibiotics and chemotherapeutics	251
	H ₁ and H ₂ histamine antagonists	255
	Antifungal drugs	257
	Antiprotozoal drugs	259
	Drugs used in leprosy	259
	Drugs used in tuberculosis	261
	Antimalarials	262
	Oral retinoids	263
	Propantheline	268
	Colchicine	269
	D-Penicillamine	269
	Acyclovir	270

SECTION V. SIDE EFFECTS OF COSMETICS

Chapter 20.	Side effects of cosmetics: introduction	282
	Cosmetics: what they do	282
	Risk increasing factors for adverse skin reactions	282
	Nature of side effects	282
	Incidence of side effects	283
	Incidence of side effects from the various cosmetic product categories	283
Chapter 21.	Patch testing with cosmetic preparations	292
Chapter 22.	Hair cosmetics	295
	Shampoo and anti-dandruff shampoo	295
	After-shampoo rinses or hair conditioners	297
	Hair colors	299
	Permanent wave	303
	Hairspray and hairsetting lotions	305
	Hair bleach	306
	Hair dressing	307
	Hair straightener (hair relaxer)	309
	Hair growth promotion	310
	Contact allergy to ingredients of hair preparations (shampoos and colors excluded)	311
	Other side effects of hair preparations (shampoos and colors excluded)	312
Chapter 23.	Face cosmetics	316
	Face cream (moisturizing cream)	316
	Cleansing lotion	318
	Facial make-up	319
	Face masks	320
	Aftershave	322
	Other shaving aids	323
	Eye make-up	324
	Anti-acne products	326
	Camouflage and greasepaint ('schmink')	328
	Toothpastes and mouthwashes	328
	Contact allergy to ingredients of facial cosmetics	329
	Lipstick and lip balm	332
	Contact allergy to lipstick ingredients	333
Chapter 24.	Nail cosmetics	337
	Contact allergy to ingredients of nail cosmetics	340
	Other side effects of ingredients of nail cosmetics	341
Chapter 25.	Cosmetics for the body and parts of the body	343
	Bath and shower cosmetics	343

	Contact allergy to ingredients of bath, shower and body cosmetics	345
	Hand and body lotion	345
	Body talc	346
	Soap	347
	Fluid soap and hand cleaner	349
	Depilatory preparations	351
	Skin bleaching agents	353
	Contact allergy to ingredients of skin bleaching agents	354
	Other adverse reactions to ingredients of skin bleaching agents	354
	Deodorant-antiperspirant	355
	Contact allergy to ingredients of deodorants, antiperspirants and feminine hygiene cosmetics	358
	Body make-up	360
	Sun and solaria cosmetics	360
	Sport and massage oils	367
	Foot cosmetics	369
	Barrier cream	371
Chapter 26.	Plant products in cosmetics	377
	Side effects of some plants and plant products used in cosmetics	380
Chapter 27.	Tabulation of ingredients of cosmetics	389
	<i>Antimicrobials and antioxidants</i>	390
	Antioxidants and chelating agents	390
	Acids, esters, alcohols, amides	392
	Formaldehyde and donor compounds	393
	Mercurials	394
	Phenols, halogenated phenols, organohalogen compounds	394
	Cationic compounds	395
	All other antimicrobials	396
	<i>Fragrance materials</i>	397
	<i>Colors</i>	431
	Conversion of CTFA/FDA names to Color Index numbers (CI)	432
	Color ingredients of hair dye preparations	449
	<i>Sunscreens</i>	452
	<i>Lipids and surfactants</i>	455
	Lipids (hydrocarbons, fatty acids, fatty alcohols, esters and silicones)	456

Anionic surfactants	461
Cationic surfactants	463
Non-ionic surfactants	469
Amphoteric surfactants	475
Amines - aminoalkanols	476
Polyols (polyalcohols)	477
<i>Miscellaneous cosmetic ingredients</i>	479
Index	493

1. Contact dermatitis

INTRODUCTION

- 1.1 Dermatitis and eczema are names used to indicate a special inflammatory state of the skin; when caused by external agents, this reaction is termed contact dermatitis or contact eczema.
- 1.2 Contact dermatitis may be classified as follows:
- Acute toxic contact dermatitis
 - Irritant contact dermatitis
 - Allergic contact dermatitis
 - Phototoxic contact dermatitis
 - Photoallergic contact dermatitis

MORPHOLOGICAL ASPECTS OF CONTACT DERMATITIS

- 1.3 An *acute allergic* contact dermatitis is characterized by polymorphy of the eruption; in the acute phase the skin reddens, clusters of minute papules, non-umbilicated vesicles and swelling occur, as well as weeping and exudation leading to the formation of crustae. The eruption is usually accompanied by itching, which may vary from moderate to quite severe. In cases of strong reactions the process may be noted to spread. In the subacute phase the polymorphy of the eruption diminishes: the skin becomes dry and scaly and fissures may be noted.

When the eruption becomes chronic, areas of the epidermis thicken, with deepening of the normal skin lines (lichenification); erythema and papules are less prominent. Multiple excoriations indicate the process to itch.

- 1.4 *Irritant* contact dermatitis often starts with dryness, itching and scaliness of the skin; papules and vesicles may develop later. In some cases it is impossible, on clinical examination, to distinguish between acute irritant dermatitis and acute allergic contact dermatitis.

2. Toxic and irritant contact dermatitis

ACUTE TOXIC CONTACT DERMATITIS

- 2.1 Acute toxic contact dermatitis may be provoked by single or repeated contacts with strongly toxic substances. The association between the injury and the toxic substance is usually quite obvious from the patient's history.

This type of reaction occurs frequently as a result of, mostly accidental, contacts with acids, alkalis, cleansers, solvents, etc.; only very rarely, however, is it caused by drugs.

IRRITANT CONTACT DERMATITIS

- 2.2 Irritant contact dermatitis is a term used to describe a localized, superficial, exudative, non-immunological inflammation of the skin, which is due to the direct influence of one or more external factors [15]. Many substances, including drugs, may after repeated contact with the skin cause irritant dermatitis by a direct action. This occurs without previous sensitization; immunological processes are not involved.

During and after the first contacts no visual alterations may be observed. After repeated contact, the skin gradually becomes erythematous; drying and cracking occurs, and later, an eczematous reaction with papules and vesicles may develop.

An irritant substance will cause dermatitis if it is permitted to act in sufficient intensity and quantity and for a sufficient length of time. Irritant reactions may develop in all persons, though the individual susceptibility varies greatly. This probably depends on the thickness of the epidermis. Irritant reactions are more easily provoked under occlusion, e.g. under adhesives and polyethylene, or in skin folds.

Differential diagnosis

- 2.3 The condition of an already eczematized skin (from whatever cause) is quickly worsened by the application of a mild irritant medicament; the resulting exacerbation may be mistaken for an allergic reaction. In such cases irritant and allergic reactions are often difficult to distinguish. The differential diagnosis between irritant and allergic contact dermatitis must be made by means of patch testing. This is sometimes rather difficult, as patch tests with mild irritants (if insufficiently diluted) may cause false positive patch test reactions, especially when they are performed on patients with an eczematous eruption elsewhere on the skin. In such circumstances even standard test substances in routine concentrations may elicit false positive reactions. The problem of false positive reactions is further discussed in § 3.18.

Topical drugs that have caused irritant dermatitis are listed in § 2.4.

2.4

Irritant dermatitis due to topical drugs

Drug	Use	Ref.
6-aminonicotinamide	psoriasis therapy	29
ammonium persulfate	hair bleaches	7
benzalkonium chloride	antiseptic	9
benzoyl peroxide	acne therapy	18
cantharidin	wart treatment	6
carmustine (BCNU)	topical cytostatic drug	39
chrysarobin	psoriasis therapy	11
citral	fragrance material	35
clioquinol	antiseptic	12
colchicine	treatment of condylomata acuminata	26
diethyltoluamide	insect repellent	41
dimethyl sulfoxide (DMSO)	solvent	14
dinitrochlorobenzene (DNCB)	treatment of alopecia areata and warts	16
dithranol (cignolin, anthralin)	psoriasis therapy	30, 33
ether	solvent	17
5-fluorouracil	topical cytostatic drug	10, 42
hexachlorophene	antiseptic	2, 28
hydroquinone	skin bleaching agent	24
6-hydroxy-1,3-benzoxathiol-2-one	psoriasis therapy	22
iodine tincture	antiseptic	13
mechlorethamine hydrochloride	treatment of mycosis fungoides	38
mesulfen	scabicide	31
monobenzyl ether of hydroquinone	skin bleaching agent	23
phenol	antipruritic	4, 21
podophyllum resin	treatment of condylomata acuminata	25
propylene glycol	vehicle constituent	27, 34, 36
quaternary ammonium compounds	antiseptics	9
resorcinol	antipruritic, peeling agent	3
retinoic acid	acne therapy	19, 40
salicylic acid	keratolytic drug	11

(continued)

2.4 Irritant dermatitis due to topical drugs

(continuation)

Drug	Use	Ref.
selenium sulfide	dandruff therapy	1
sodium lauryl sulfate	vehicle constituent	8, 32
tar	psoriasis and eczema therapy, in cosmetics	20
urea	keratolytic drug, enhances penetration of chemicals through the skin	5, 37

2.5 REFERENCES

1. Albright, S. D. and Hitch, J. M. (1966): Rapid treatment of tinea versicolor with selenium sulfide. *Arch. Derm.*, 93, 460.
2. Baker, H., Ive, F. A. and Lloyd, M. J. (1969): Primary irritant dermatitis of the scrotum due to hexachlorophene. *Arch. Derm.*, 99, 693.
3. Becker, S. W. and Obermayer, M. E. (1947): *Modern Dermatology and Syphilology*, 2nd Edition. J. B. Lippincott Co., Philadelphia, London, Montreal.
4. Björnberg, A. (1968): *Skin Reactions to Primary Irritants in Patients with Hand Eczema*. O. Isacsons Tryckeri, Gothenburg.
5. Colin Hindson, M. T. (1971): Urea in the topical treatment of atopic eczema. *Arch. Derm.*, 104, 284.
6. Dilaimy, M. (1975): Lymphangitis caused by cantharidin. *Arch. Derm.*, 111, 1073.
7. Fisher, A. A. and Doms-Gossens, A. (1976): Persulfate hair bleach reactions. *Arch. Derm.*, 112, 1407.
8. Fisher, A. A. and Pascher, F. (1971): Allergic contact dermatitis due to ingredients of vehicles. *Arch. Derm.*, 104, 286.
9. Gall, H. (1979): Toxisches Kontaktekzem auf die quaternäre Ammonium-Verbindung Benzalkoniumchlorid. *Dermatosen Beruf Umw.*, 27, 139.
10. Goette, D. K., Odom, R. B. and Owens, R. (1977): Allergic contact dermatitis from topical fluorouracil. *Arch. Derm.*, 113, 196.
11. Goodman, L. S. and Gilman, A. (Eds.) (1970): *The Pharmaceutical Basis of Therapeutics*, 4th Edition. The MacMillan Co., London, Toronto.
12. Kero, M., Hannuksela, M. and Sothman, A. (1979): Primary irritant dermatitis from topical clioquinol. *Contact Dermatitis*, 5, 115.
13. Kirchmayr, W. (1957): Zum Problem der sogenannten Jodüberempfindlichkeit. *Wien. klin. Wschr.*, 69, 578.
14. Kligman, A. M. (1965): Topical pharmacology and toxicology of dimethylsulfoxide. Part 1 and 2. *J. Amer. med. Ass.*, 193, 796 and 923.
15. Malten, K. E. (1981): Thoughts on irritant contact dermatitis. *Contact Dermatitis*, 7, 238.
16. The Merck Index: *An Encyclopedia of Chemicals and Drugs*, 9th Edition (1976): Merck and Co., Inc., Rahway, U.S.A.
17. Michel, P. J. (1952): Les dermites de l'éther. *J. Méd. Lyon*, 33, 741.
18. Pace, W. E. (1965): Benzoyl peroxide-sulfur cream for acne vulgaris. *Canad. med. Ass. J.*, 93, 252.
19. Peachy, R. D. G. and Connor, B. L. (1971): Topical retinoic acid in the treatment of acne vulgaris. *Brit. J. Derm.*, 85, 462.
20. Rothenborg, H. W. and Hjorth, N. (1968): Allergy to perfumes from toilet soaps and detergents in patients with dermatitis. *Arch. Derm.*, 97, 417.
21. Rubin, M. B. and Pirozzi, D. J. (1973): Contact dermatitis from carbolated vaseline. *Cutis*, 12, 52.
22. Schoeflinus, H. H. (1972): Kontaktdermatitis mit erhöhter Körpertemperatur unter Behandlung von Psoriasis vulgaris capitis mit einem Benzoxathiol-Derivat. *Z. Haut- u. Geschl.kr.*, 47, 227.
23. Spencer, M. C. (1962): Leukoderma following monobenzyloether of hydroquinone bleaching. *Arch. Derm.*, 86, 615.
24. Spencer, M. C. (1965): Topical use of hydroquinone for depigmentation. *J. Amer. med. Ass.*, 194, 962.
25. Sullivan, M. and King, L. S. (1947): Effects of resin of podophyllum on normal skin, condylomata acuminata and verrucae vulgares. *Arch. Derm. Syph.*, 56, 30.

26. Von Krogh, G. and Rudén, A. K. (1980): Topical treatment of penile condylomata acuminata with colchicine at 48-72 hours intervals. *Acta derm.-venereol. (Stockh.)*, 60, 87.
27. Warshaw, T. G. and Herrmann, F. (1952): Studies of skin reactions to propylene glycol. *J. invest. Derm.*, 19, 423.
28. Watt, T. L. and Baumann, R. R. (1972): Primary irritant dermatitis caused by pHisoHex. *Cutis*, 10, 363.
29. Zackheim, H. S. (1975): Treatment of psoriasis with 6-amino-nicotinamide. *Arch. Derm.*, 111, 880.

UPDATE - 2nd Edition

30. Puschmann, M. and Schmersahl, P. (1983): Untersuchungen zur Frage der Nebenwirkungen von Anthralin und seinen beiden Hauptverunreinigungen an der gesunden Haut. *Z. Hautkr.*, 58, 410.
31. Meneghini, C. L., Vena, G. A. and Angelini, G. (1982): Contact dermatitis to scabicides. *Contact Dermatitis*, 8, 285.
32. Bruynzeel, D. P., van Ketel, W. G., Scheper, R. J. and von-Blomberg-van der Flier, B. M. E. (1982): Delayed time course of irritation by sodium lauryl sulfate: Observations on threshold reactions. *Contact Dermatitis*, 8, 236.
33. Kingston, T. and Marks, R. (1983): Irritant reactions to dithranol in normal subjects and psoriatic patients. *Brit. J. Derm.*, 108, 307.
34. Andersen, K. E. and Storrs, F. J. (1982): Hautreizungen durch Propylenglykol. *Hautarzt*, 33, 12.
35. Rothenborg, H. W., Menné, T. and Sjölin, K.-E. (1977): Temperature dependent primary irritant dermatitis from lemon perfume. *Contact Dermatitis*, 3, 37.
36. Trancik, R. J. and Maibach, H. I. (1982): Propylene glycol: irritation or sensitization? *Contact Dermatitis*, 8, 185.
37. Cramers, M. and Thormann, J. (1981): Skin reactions to an urea-containing cream. *Contact Dermatitis*, 7, 189.
38. Hamminga, B., Noordijk, E. M. and van Vloten, W. A. (1982): Treatment of mycosis fungoides. *Arch. Derm.*, 118, 150.
39. Zackheim, H. S., Epstein, E. H. Jr., McNutt, N. et al. (1983): Topical carmustine (BCNU) for mycosis fungoides and related disorders: A 10-year experience. *J. Amer. Acad. Derm.*, 9, 363.
40. Thomas, J. R. III and Doyle, J. A. (1981): The therapeutic uses of topical vitamin A acid. *J. Amer. Acad. Derm.*, 4, 505.
41. Reuveni, H. and Yagupsky, P. (1982): Diethyltoluamide-containing insect repellent. *Arch. Derm.*, 118, 582.
42. Goette, D. K. (1981): Topical chemotherapy with 5-fluorouracil. *J. Amer. Acad. Derm.*, 4, 633.